Enlivex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K report covers the month of March 2025, with the filing date of March 17, 2025. Enlivex Therapeutics Ltd., an Israeli company, reported a significant intellectual property milestone regarding its product Allocetra®.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory update and does not contain financial statements.
Material Changes
The primary material event is the issuance of a notice of allowance by the China National Intellectual Property Administration for patent application number 2020800620493. This development secures intellectual property protection in China for methods of using Allocetra® to treat osteoarthritis.
Outlook, Risks, and Management Commentary
Management highlights that the resulting patent, once issued, will provide protection through at least 2040. The filing does not contain specific financial guidance, risk factors, or contingencies beyond the standard incorporation of the press release.
Key Facts for Investor Verification
- China National Intellectual Property Administration issued a notice of allowance for patent application 2020800620493.
- The patent covers methods of using Allocetra® for treating osteoarthritis.
- Expected patent protection in China extends through at least 2040.
- The patent is not yet issued; the current status is a notice of allowance.